Use of TLR-2 antagonists for treatment of reperfusion injury and tissue damage

The present invention provides compounds and methods for the treatment and prophylaxis of ischemia reperfusion injury. In particular the invention provides compounds which function to suppress Toll-like Receptor 2 biological function or expression.

Saved in:
Bibliographic Details
Main Authors FATIH ARSLAN, BRIAN KEOGH, LUKE O'NEILL, DOMINIQUE DE KLEIJN, GERARD PASTERKAMP, PETER MCGUIRK, CHRISTOPHER LOCHER, MARK HEFFERNAN
Format Patent
LanguageEnglish
Published 12.02.2009
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present invention provides compounds and methods for the treatment and prophylaxis of ischemia reperfusion injury. In particular the invention provides compounds which function to suppress Toll-like Receptor 2 biological function or expression.
Bibliography:Application Number: AU20080285626